Pre-Header Contact

800-449-3353 | |

Footer Socials

Pre-Header Menu

Careers | Contact Us

Investor Relations

Press Release Details

Rockwell Medical Reports Fourth Quarter and Full Year 2010 Results

March 3, 2011 at 7:30 AM EST

2010 Gross Profit up $2 Million; Net Loss Decreased $2.8 Million

 Conference call at 8:30am ET to discuss results

WIXOM, Mich., March 3, 2011 (GLOBE NEWSWIRE) -- Rockwell Medical (Nasdaq:RMTI), a fully-integrated biopharmaceutical company offering innovative products and services targeting end-stage renal disease (ESRD), chronic kidney disease (CKD) and iron deficiency anemia, reported today fourth quarter and full-year 2010 results:

Fourth Quarter Financial Highlights

  • Sales were $14.3 million, a 3% decrease compared to the fourth quarter of 2009.
  • Gross profit margin increased to 16.6%, compared to gross profit margin of 16.4% in the fourth quarter of 2009.
  • R&D expense was $1.7 million, compared to $1.1 million in the fourth quarter 2009.
  • Net loss of ($1.7) million, compared to a net loss of ($0.5) million in the fourth quarter 2009.

2010 Financial Highlights

  • Sales were $59.6 million, an increase of $4.8 million or 8.8%, compared to 2009.
  • Gross profit margins were 16.6%, an increase of 2.2 percentage points compared to gross profit margin of 14.4% in 2009.
  • Gross profit increased $2 million or 25% to $9.9 million compared to $7.9 million in 2009.
  • R&D expense was $3.4 million compared to $6.5 million in 2009.
  • Net loss of ($2.7) million, compared to a net loss of ($5.5) million in 2009.
  • Net loss includes non-cash equity compensation charges of $ 4.0 million.
  • Year-end cash position of $24.2 million.

Drug Development & Corporate Progress

  • Commenced patient screening for Phase III CRUISE clinical trials.
  • Submitted Phase III study protocol to FDA and completed site feasibility study.
  • Confirmed acceptable Phase III primary efficacy endpoint with FDA.
  • Commenced patient enrollment for ESA-sparing PRIME study.
  • Presented new ESA sparing and iron repletion data at ASN 2010.
  • Received U.S. patent for proprietary SFP formula extending intellectual property protection to 2029.
  • Appointed Dr. Ajay Singh and Dr. Ian Macdougall to Scientific Advisory Board.
  • Hired VP of Business Development/Investor Relations.

Mr. Robert L. Chioini, Chairman and CEO stated, "We had a very productive year. We moved our SFP clinical development significantly forward and we expect to begin enrolling patients into our Phase III CRUISE studies this quarter. We have also begun enrolling patients into our PRIME study, which is designed to capture ESA dose reduction for patients receiving SFP-iron during dialysis. Regarding our operating business, which provides a ready-made channel to sell SFP into the dialysis provider market upon FDA approval, both sales and margins continued to improve. Moving into 2011, we look forward to continuing to build both our operating and drug businesses, progressing SFP through Phase III and closer to commercialization."

Conference Call Information:

Rockwell Medical will be hosting a conference call to review its 2010 fourth quarter results on Thursday, March 3, 2011 at 8:30 am ET. Investors are encouraged to call a few minutes in advance at (877) 383-7438 or to listen to the call on the web at:

About CRUISE Phase III Trials:

Rockwell is conducting two pivotal Phase III clinical trials for SFP. Each study is a prospective, randomized, double-blinded, placebo-controlled, multicenter study to demonstrate efficacy and safety of SFP-iron, delivered via dialysate in adult CKD patients requiring hemodialysis. Each study will comprise 300 patients, randomized equally between SFP and placebo groups over a period of up to 12 months. 

About SFP:

SFP is a novel, investigational, continuous iron therapy in late-stage clinical development, designed to treat iron deficiency anemia in ESRD patients.  In contrast to intravenous (IV) iron delivery, SFP is a proprietary, water-soluble iron that travels to the bloodstream and binds directly to apo-transferrin and then travels to bone marrow to assist in forming a healthy red blood cell, similar to normal physiologic dietary iron intake.  SFP is a continuous iron replacement treatment, delivering small doses of iron during every dialysis session, to replenish the 5-7mg of iron lost during the dialysis procedure, thereby maintaining hemoglobin in the target range as per Kidney Disease Quality Outcomes Initiative (KDQOI) recommendations. Clinical trial data to date suggests that SFP, delivered via dialysate during each dialysis treatment, maintains optimal iron balance and avoids liver toxicity while decreasing associated drug administration costs. Academic studies have shown that more frequent maintenance doses of iron improve therapeutic response to erythropoiesis-stimulating agents (ESA's), thereby decreasing the ESA doses needed to maintain hemoglobin in the target range. Rockwell has licensed exclusive world-wide rights to manufacture and sell SFP and has obtained patent protection for SFP in multiple countries, including the three largest dialysis markets in the world: the United States, Japan, and the European Union. Based on current market data, the U.S. dialysis market for IV iron is approximately $560 million annually while global market potential is approximately $1 billion.

For a demonstration of SFP's unique mechanism of action, please view the animation video at

About Rockwell Medical:

Rockwell Medical is a fully-integrated biopharmaceutical company offering innovative products and services initially targeting end-stage renal disease (ESRD), chronic kidney disease (CKD), and iron deficiency anemia. An established manufacturer and leader in delivering high-quality hemodialysis concentrates/dialysates to dialysis providers and distributors in the U.S. and abroad, Rockwell provides products that are used to maintain human life by removing toxins and replacing critical nutrients in the dialysis patient's bloodstream. Dialysis is a process that duplicates kidney function for patients who suffer from ESRD.  There are approximately 400,000 ESRD patients in the United States.  World-wide there are approximately 2 million ESRD patients, growing at an annual rate of 5-6 percent.

The Company is currently developing unique, proprietary renal drug therapies for iron treatment. These exclusive renal drug therapies support disease management initiatives to improve the quality of life and care of dialysis patients and are designed to deliver safe and effective therapy, while decreasing drug administration costs and improving patient convenience. Rockwell Medical is developing a pipeline of drug therapies, including extensions of SFP for indications outside of hemodialysis. Please visit for more information.

The Rockwell Medical Technologies, Inc. logo is available at

Certain statements in this press release constitute "forward-looking statements" within the meaning of the federal securities laws. Words such as "may," "might," "will," "should," "believe," "expect," "anticipate," "estimate," "continue," "predict," "forecast," "project," "plan", "intend" or similar expressions, or statements regarding intent, belief, or current expectations, are forward-looking statements. While the Company believes these forward-looking statements are reasonable, undue reliance should not be placed on any such forward-looking statements, which are based on information available to us on the date of this release. These forward looking statements are based upon current estimates and assumptions and are subject to various risks and uncertainties, including without limitation those set forth in Rockwell Medical's SEC filings. Thus, actual results could be materially different. Rockwell Medical expressly disclaims any obligation to update or alter statements whether as a result of new information, future events or otherwise, except as required by law.

For the three and twelve months ended December 31, 2010 and December 31, 2009
  Three Months Three Months Year Ended Year Ended
  Ended Ended    
   December 31, 2010
December 31, 2009 
December 31,
December 31,
Sales $ 14,322,514 $ 14,761,487 $  59,554,592 $ 54,729,505
Cost of Sales 11,947,062 12,333,924 49,693,753 46,842,334
Gross Profit 2,375,452 2,427,563 9,860,839 7,887,171
Selling, General and Administrative 2,460,015 1,836,125 9,307,621 6,914,198
Research and Product Development  1,735,468 1,141,853 3,422,134 6,454,352
Operating Income (Loss) (1,820,031) (550,415) (2,868,916) (5,481,379)
Interest and Dividend Income 157,577 5,320 195,218 5,320
Interest (Income) Expense, net    825  4,686    9,701  25,179
(Loss) Before Income Taxes (1,663,279) (549,781) (2,683,399) (5,501,238)
Income Tax Expense  --  --  --  --
Net Income (Loss) $ (1,663,279) $ (549,781) $ (2,683,399) $ (5,501,238)
Basic Earnings (Loss) per Share  $ (0.10) $ (0.03) $ (0.16) $ (0.37)
Diluted Earnings (Loss) per Share  $ (0.10) $ (0.03) $ (0.16) $ (0.37)
As of December 31, 2010 and 2009
  December 31,
 December 31,
Cash and Cash Equivalents $ 12,263,449 $ 23,038,095
Investments Available for Sale 11,938,098 --
Accounts Receivable, net of a reserve of $23,000 in 2010 and $31,000 in 2009 4,507,296 3,492,622
Inventory 2,936,878 3,088,352
Other Current Assets 1,020,647 329,876
Total Current Assets 32,666,368 29,948,945
Property and Equipment, net 3,049,513 3,631,549
Intangible Assets 166,657 214,337
Goodwill 920,745 920,745
Other Non-current Assets  163,624  163,645
Total Assets $ 36,966,907 $ 34,879,221
Capitalized Lease Obligations $ 18,215 $ 42,938
Accounts Payable 3,659,507 3,388,757
Accrued Liabilities 2,577,022 1,854,347
Customer Deposits  165,476  250,915
Total Current Liabilities  6,420,220  5,536,957
Capitalized Lease Obligations 8,750 19,062
Shareholders' Equity:    
Common Shares, no par value, 17,513,608 and 17,200,442 shares issued and outstanding 57,017,236 53,545,394
Common Share Purchase Warrants, 3,338,569 and 3,318,569 warrants issued and outstanding 8,275,509 7,635,594
Accumulated Deficit (34,541,185) (31,857,786)
Accumulated Other Comprehensive Loss  (213,623)  --
Total Shareholders' Equity  30,537,937  29,323,202
Total Liabilities And Shareholders' Equity $ 36,966,907 $ 34,879,221
For the years ended December 31, 2010 and 2009
  2010 2009
Cash Flows From Operating Activities:    
Net (Loss) $ (2,683,399) $ (5,501,238)
Adjustments To Reconcile Net Loss To Net Cash Used In    
Operating Activities:    
Depreciation and Amortization 1,389,152 1,233,706
Share Based Compensation — Non-employee warrants 639,915 403,203
Share Based Compensation- Employees 3,381,394 1,949,684
Loss on Disposal of Assets 19,816 36,415
Changes in Assets and Liabilities:    
(Increase) Decrease in Accounts Receivable (1,014,674) 1,737,034
(Increase) Decrease in Inventory 151,474 73,273
(Increase) Decrease in Other Assets (690,750) 68,131
Increase (Decrease)in Accounts Payable 270,750 (1,822,215)
Increase in Other Liabilities  637,236  395,248
Changes in Assets and Liabilities  (645,964)  451,471
Cash Provided By (Used) In Operating Activities 2,100,914 (1,426,759)
Cash Flows From Investing Activities:    
Purchase of Investments Available for Sale (12,151,721) --
Purchase of Equipment (772,364) (1,595,999)
Proceeds on Sale of Assets 1,800  --
Purchase of Intangible Assets  --  (4,949)
Cash (Used) In Investing Activities (12,922,285) (1,600,948)
Cash Flows From Financing Activities:    
Proceeds from Issuance of Common Shares and Purchase Warrants 90,448 20,650,610
Payments on Notes Payable and Capital Lease Obligations (43,723) (181,453)
Cash Provided By Financing Activities 46,725 20,469,157
Increase (Decrease) In Cash (10,774,646) 17,441,450
Cash At Beginning Of Period 23,038,095 5,596,645
Cash At End Of Period $  12,263,449 $  23,038,095
CONTACT: Carl Belczynski, VP Investor Relations

         Rockwell Medical

         (248) 960-9009

         Brian Korb, VP

         The Trout Group LLC

         (646) 378-2923

Rockwell Medical Technologies, Inc. Logo

Source: Rockwell Medical Technologies, Inc.

News Provided by Acquire Media

Shareholder Tools

Email Alerts
RSS News Feeds